Adrian Rawcliffe is CEO at Adaptimmune Therapeutics PLC (ADAP). They have made 25 open-market trades across 2 companies since 2018, most recently 2026-08-12.
CIK 0001555851
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 25 sales. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| WVE | SELL · 10b5-1 | 2026-08-12 | 2026-08-13 | $5.29 | $67K | +1.5% | -11.6% | — |
| WVE | SELL · 10b5-1 | 2025-12-08 | 2025-12-10 | $15.00 | $630K | -9.3% | -30.2% | -30.6% |
| WVE | SELL · 10b5-1 | 2025-11-13 | 2025-11-14 | $6.79 | $219K | +8.2% | +127.2% | +80.5% |
| ADAP | SELL | 2025-01-17 | 2025-01-17 | $0.58 | $18K | +7.0% | +2.3% | -58.1% |
| ADAP | SELL | 2025-01-13 | 2025-01-15 | $0.58 | $35K | -0.5% | -2.5% | -57.9% |
| ADAP | SELL | 2024-01-16 | 2024-01-17 | $0.70 | $28K | +10.3% | +66.8% | +43.1% |
| ADAP | SELL | 2024-01-11 | 2024-01-12 | $0.85 | $25K | -6.7% | +53.2% | +63.3% |
| ADAP | SELL | 2023-09-01 | 2023-09-01 | $0.78 | $2K | +4.4% | -3.8% | -35.9% |
| ADAP | SELL | 2023-06-27 | 2023-06-27 | $0.92 | $2K | +2.8% | -3.6% | -15.8% |
| ADAP | SELL | 2023-01-17 | 2023-01-17 | $1.86 | $19K | +2.9% | -2.3% | -20.6% |
| ADAP | SELL | 2023-01-11 | 2023-01-12 | $1.73 | $55K | +2.2% | -13.9% | -33.9% |
| ADAP | SELL | 2023-01-04 | 2023-01-04 | $1.69 | $9K | -3.3% | -8.3% | -43.1% |
| ADAP | SELL | 2022-09-01 | 2022-09-01 | $1.97 | $5K | -15.4% | -44.6% | +11.3% |
| ADAP | SELL | 2022-06-27 | 2022-06-27 | $1.63 | $4K | +10.0% | +7.6% | -29.4% |
| ADAP | SELL | 2022-01-18 | 2022-01-18 | $3.19 | $35K | -12.7% | -2.3% | -40.1% |
| ADAP | SELL | 2022-01-11 | 2022-01-13 | $3.56 | $113K | -15.8% | -7.5% | -41.5% |
| ADAP | SELL | 2022-01-04 | 2022-01-05 | $4.06 | $22K | -14.3% | -21.3% | -39.2% |
| ADAP] | SELL | 2021-09-01 | 2021-09-01 | $5.20 | $14K | N/A | N/A | N/A |
| ADAP | SELL | 2021-06-28 | 2021-06-28 | $4.37 | $12K | -6.4% | -16.7% | +32.9% |
| ADAP | SELL | 2021-01-19 | 2021-01-19 | $5.67 | $112K | -6.8% | +2.0% | -20.1% |
| ADAP | SELL | 2021-01-12 | 2021-01-12 | $6.15 | $17K | -1.4% | +13.7% | -14.8% |
| ADAP | SELL | 2021-01-04 | 2021-01-05 | $5.33 | $26K | +1.3% | +3.5% | -0.6% |
| ADAP | SELL | 2020-09-01 | 2020-09-02 | $8.51 | $24K | +22.1% | -2.9% | -42.4% |
| ADAP | SELL | 2020-08-03 | 2020-08-04 | $9.25 | $26K | -9.3% | -11.4% | -41.7% |
| ADAP | SELL | 2020-01-14 | 2020-01-15 | $5.13 | $17K | -5.3% | -3.8% | -17.5% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.